ResMed Earnings Reflect Increased Demand For Sleep Devices, Performance Indicates Positive Dynamics, Opportunities
ResMed Earnings Reflect Increased Demand For Sleep Devices, Performance Indicates Positive Dynamics, Opportunities
Income from operations increased 38%; non-GAAP income from operations up 30%.ResMed Inc. (NYSE:RMD) reported fourth-quarter 2024 revenue of $1.22 billion, up 9% year-over-year and up 10% on a constant currency basis, in line with the consensus of $1.22 billion.
瑞思迈公司（NYSE：RMD）报告2024年第四季度营业收入为12.2亿美元，同比增长9％，按恒定汇率计算同比增长10％，符合市场预期。
The growth was driven by increased demand for sleep devices and masks portfolio and strong growth across Software as a service business.
增加睡眠设备和口罩系列产品的需求以及软件服务业务的强劲增长推动了销售增长。
Gross margin improved 350 bps to 58.5%; non-GAAP gross margin improved 330 bps to 59.1%, mainly due to reduced freight and manufacturing cost improvements, increased average selling prices, and a favorable product mix.
毛利率提高了350个基点，至58.5％；非通用会计准则毛利率提高了330个基点，至59.1％，主要是由于运费和制造成本的降低、平均售价的提高和产品结构的优化。
Income from operations increased 38%; non-GAAP income from operations up 30%.
营业收入增长了38％，非通用会计准则下的营业收入增长了30％。
The company reported adjusted EPS of $2.08, up from $1.60 a year ago, beating the consensus of $2.07.
公司报告调整后每股收益为2.08美元，比去年同期的1.60美元增长，超过市场预期的2.07美元。
The company increased its quarterly dividend by 10% to 53 cents per share.
公司将每股股息提高了10％至53美分。
William Blair writes that despite the short-term impact of the GLP-1 issue, ResMed's strong quarterly performance indicates positive market dynamics and opportunities.
威廉·布莱尔（William Blair）称，尽管糖尿病胰高血糖素样肽( GLP-1)问题短期影响公司股价，但瑞思迈公司强劲的季度业绩显示市场动态和机遇都是积极的。
"With catalysts to come from margin expansion, new product launches, and the recent resolution to the competitive consent decree, we believe the fundamentals of the business remain positive," the analyst highlights.
该分析师强调：“随着利润率扩大、新产品推出以及竞争性同意书的最近解决，我们认为公司的基本面仍然是积极的，存在诱因。”
ResMed trades at 24.9 times the consensus 2024 EPS of $8.26 below its high-growth large-cap peers.
瑞思迈公司的市盈率为24.9倍市场预期的2024年每股收益8.26美元，低于类似规模的高增长大型股票公司。
The analyst keeps the Outperform rating.
分析师保持“跑赢大盘”评级。
In June, Eli Lilly And Co (NYSE:LLY) released detailed results from the SURMOUNT-OSA phase 3 trials evaluating tirzepatide injection (10 mg or 15 mg) for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, with and without positive airway pressure (PAP) therapy.
6月，礼来公司（NYSE：LLY）公布了SURMOUNt-OSA 3期临床试验的详细结果，评估针对有肥胖症并患有中度至重度阻塞性睡眠呼吸暂停（OSA）成人的tirzepatide注射治疗，其中包括和不包括正压通气（PAP）治疗。
Price Action: RMD stock is down 2.02% at $210.23 at last check Friday.
RMD股票最后一次检查时下跌2.02％，报210.23美元。
- Healthcare Logistics Provider Owens & Minor Calls Q2 Performance Consistent With Expectations, Reiterates Annual Guidance.
- 医疗物流提供商Owens＆Minor表示，第二季度业绩符合预期，并重申全年指引。
